Thyroid Hormone Status Interferes with Estrogen Target Gene Expression in Breast Cancer Samples in Menopausal Women

Table 1

Tumor staging, immunohistochemistry, and serum dosage of breast cancer patients.

Case number	Staging	Immunohistochemistry	Serum dosage
			TPOAb^(1) (UI/mL)	TSH^(2) (μI/mL)	FT4^(3) (ng/dL)	E2^(4) (pg/mL)
1^a	T(2) N(1) M(0)	ER(+); PR(+)	11.50	0.03	3.38	<20.00
2	T(2) N(0) M(0)	ER(+); PR(−)	<10.00	3.03	1.48	26.70
3	T(2) N(0) M(0)	ER(−); PR(−)	22.30	1.22	1.78	<20.00
4	T(1) N(0) M(0)	ER(+); PR(+)	22.90	0.96	1.44	26.80
5^a	T(2) N(0) M(0)	ER(+); PR(+)	<10.00	0.30	1.94	<20.00
6^b,c	T(1) N(2) M(0)	ER(+); PR(+)	354.00	5.11	1.26	<20.00
7	T(2) N(1) M(0)	ER(+); PR(−)	<10.00	1.85	2.30	26.90
8	T(2) N(0) M(0)	ER(+); PR(−)	23.90	1.83	1.75	26.10
9	T(1) N(0) M(0)	ER(+); PR(+)	13.50	1.34	1.85	28.20
10	T(2) N(1) M(0)	ER(−); PR(+)	18.40	0.92	1.85	23.80
11^b	T(2) N(0) M(0)	ER(+); PR(+)	<10.00	4.47	1.39	<20.00
12	T(2) N(0) M(0)	ER(+); PR(−)	<10.00	1.60	1.53	<20.00
13	T(2) N(1) M(0)	ER(+); PR(+)	11.90	1.80	1.77	<20.00
14^a	T(1) N(0) M(0)	ER(+); PR(−)	<10.00	0.29	3.06	26.70
15	T(2) N(0) M(0)	ER(+); PR(+)	15.70	0.76	1.78	24.50

(1)Thyroid peroxidase antibody (TPOab): <35.00 UI/mL = negative.
⁽²⁾Thyroid-stimulating hormone (TSH): normality between 0.4 and 4.0 mUI/mL.
⁽³⁾Free thyroxine (FT4): normality between 0.8 and 1.9 ng/dL.
⁽⁴⁾Estradiol (E2): normality on postmenopause between 0 and 30 pg/mL.
^aHyperthyroidism.
^bSubclinical hypothyroidism.
^cTPOab positive.